Metraipolis › archive › dc_ccbf6ae5fa8b

Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial — Europe PMC PMID:41664938

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41664938
DOI: 10.2340/1651-226x.2026.45086
License (as archived): solo-consultazione
Archived: 2026-11-05T23:44:13.404Z
SHA-256 of the archived text: cfbf4027acc9a10532bdf2d471d11c204d5435dc1d27fbf09ba561120a1e222c
Stable URL of this page: https://metraipolis.com/documento/dc_ccbf6ae5fa8b

How to cite

Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial — Europe PMC PMID:41664938 — Europe PMC (en), https://europepmc.org/article/MED/41664938 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ccbf6ae5fa8b (Metraipolis archive dc_ccbf6ae5fa8b, sha256 cfbf4027acc9a10532bdf2d471d11c204d5435dc1d27fbf09ba561120a1e222c)

BibTeX

@misc{dcccbf6ae5fa8b,
  title = {Clinical outcomes of genomically guided trametinib monotherapy across cancer types: results from the IMPRESS-Norway trial — Europe PMC PMID:41664938},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41664938},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ccbf6ae5fa8b; sha256 cfbf4027acc9a10532bdf2d471d11c204d5435dc1d27fbf09ba561120a1e222c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41664938. Agents can read the archived copy with the MCP tool read_document.